02581nas a2200289 4500008004100000245011800041210006900159260001500228300001000243490000600253520171800259653001701977653002201994653002202016653001802038653000902056653002602065653002102091100001802112700001602130700002202146700002002168700002102188700001302209700001502222856005402237 2015 eng d00aABCB1 C3435T Genetic Polymorphism and Response to Glibenclamide Therapy in Patients with Type 2 Diabetes Mellitus0 aABCB1 C3435T Genetic Polymorphism and Response to Glibenclamide  cJune 2015 a12-150 v43 a

Background: Glibenclamide is a substrate and an inhibitor of P-glycoprotein which is coded by the gene ABCB1. Objective: To study the influence of ABCB1 C3435T gene polymorphism on the therapeutic effect of glibenclamide, its plasma levels and hypoglycemic adverse effects. Materials and Methods: The study was done in Type 2 diabetes mellitus patients of South India (n=80) who were on treatment with glibenclamide as a single agent or along with metformin. From a venous blood sample, ABCB1 C3435T genetic polymorphism and plasma levels of glibenclamide were determined. The parameters were compared between genotype groups. Patient characteristics across genotypes were analyzed using one way ANOVA and the association between glycemic status and genotype was studied using Chi Square test. The association between genotypes and parameters such as C/D values, hypoglycemic episodes were compared using Kruskal Wallis Test. Results:There were no significant differences in age, body mass index and duration of treatment between the genotype groups ABCB1 CC, CT and TT. There was no significant association between glycemic status of type 2 diabetes and presence of variant genotypes ABCB1 CT and TT. There were no statistically significant differences in plasma concentration of glibenclamide, number and severity of adverse effects between the genotype groups. Conclusion: ABCB1 C3435T genetic polymorphism did not produce any significant influence on the therapeutic response to glibenclamide, plasma glibenclamide levels and the occurrence of adverse events in South Indian patients with type 2 diabetes mellitus

10aABCB1 C3435T10aDiabetes Mellitus10aDrug Transporters10aGlibenclamide10aMDR110aPersonalized Medicine10aPharmacogenetics1 aA, Surendiran1 aSC, Pradhan1 aDKS, Subrahmanyam1 aAgrawal, Aparna1 aG, Umamaheswaran1 aS, Rajan1 aC, Adithan uhttps://ijphs.org/article/2015/4/2/105530ijpcs421